A proof-of-concept clinical trial of WP-1220 for the treatment of cutaneous T-cell lymphoma (CTCL)
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs MOL 4239 (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Proof of concept; Therapeutic Use
- 24 Oct 2017 According to a Moleculin Biotech media release, the company hope to be enrolling patients near year-end.
- 14 Sep 2017 New trial record
- 13 Sep 2017 According to a Moleculin Biotech media release, the company is planning to apply to the Polish regulatory authorities for a clinical trial authorization.